Inducing Systemic Immunity and Regressions in Metastatic Melanoma
Status and phase
Conditions
Treatments
Details and patient eligibility
About
In patients with multiple metastatic nodules of melanoma, the investigators evaluated whether autologous cytokines injected into cutaneous metastases would induce a systemic immune response as evidenced by the accumulation of dense lymphocytic infiltrates in metastases that had never been injected. Such immune responses were observed, and often the never-injected metastasis regressed completely. 20% of patients remained free of disease for greater than 5 years.
Full description
Lymphocytic infiltrates were seen in never-injected nodules only after several weeks of injections elsewhere. No adverse events were seen. The tumor-infiltrating lymphocytes were able to kill autologous melanoma ex vivo. Some patients who experienced complete regressions of all metastases lived without disease for over 10 years.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Multiple cutaneous or subcutaneous metastases of melanoma
Exclusion criteria
- Visceral metastases on admission.
- No current chemotherapy or immunotherapy.
- Note study performed between 1978 and 2002 before current therapies were available.
Trial design
Primary purpose
Allocation
Interventional model
Masking
88 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal